Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tovinontrine (IMR-687) in Beta Thalassemia
NCT04411082Phase 2Terminated
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of tovinontrine in beta thalassemia, sponsored by Cardurion Pharmaceuticals. Started Oct 2020; status: terminated.
02
Drugs
tovinontrine
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT04411082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04411082.